Equities analysts predict that Calyxt Inc (NASDAQ:CLXT) will report sales of $1.15 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Calyxt’s earnings. The lowest sales estimate is $300,000.00 and the highest is $2.00 million. Calyxt reported sales of $190,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 505.3%. The company is expected to announce its next quarterly earnings report on Tuesday, March 12th.

On average, analysts expect that Calyxt will report full-year sales of $1.35 million for the current year, with estimates ranging from $500,000.00 to $2.20 million. For the next financial year, analysts forecast that the firm will post sales of $12.45 million, with estimates ranging from $11.40 million to $13.50 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Calyxt.

Calyxt (NASDAQ:CLXT) last posted its earnings results on Wednesday, November 14th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.06. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.50 million. Calyxt had a negative net margin of 6,256.67% and a negative return on equity of 33.08%.

A number of equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Calyxt from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Thursday. Jefferies Financial Group reissued a “buy” rating and issued a $27.00 price target on shares of Calyxt in a research note on Thursday, November 15th. Citigroup dropped their price target on shares of Calyxt from $19.00 to $13.00 and set a “neutral” rating on the stock in a research note on Monday, November 19th. Finally, Goldman Sachs Group assumed coverage on shares of Calyxt in a research note on Friday, September 7th. They issued a “neutral” rating and a $18.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Calyxt currently has a consensus rating of “Buy” and a consensus target price of $20.85.

In other Calyxt news, insider Daniel F. Voytas sold 4,083 shares of Calyxt stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $13.00, for a total transaction of $53,079.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Manoj Sahoo sold 2,521 shares of Calyxt stock in a transaction on Monday, October 1st. The stock was sold at an average price of $14.84, for a total transaction of $37,411.64. The disclosure for this sale can be found here. Insiders sold a total of 20,553 shares of company stock worth $303,275 in the last three months. 2.80% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC boosted its stake in Calyxt by 134.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,583 shares of the company’s stock worth $123,000 after purchasing an additional 3,781 shares during the last quarter. PNC Financial Services Group Inc. acquired a new stake in Calyxt during the 2nd quarter worth $186,000. California Public Employees Retirement System acquired a new stake in Calyxt during the 2nd quarter worth $187,000. Granite Investment Partners LLC acquired a new stake in Calyxt during the 2nd quarter worth $216,000. Finally, Essex Investment Management Co. LLC acquired a new stake in Calyxt during the 3rd quarter worth $309,000. 28.30% of the stock is currently owned by institutional investors.

Shares of NASDAQ:CLXT traded down $0.62 during trading on Tuesday, hitting $10.37. 51,098 shares of the stock traded hands, compared to its average volume of 63,703. The company has a debt-to-equity ratio of 0.17, a current ratio of 15.01 and a quick ratio of 15.01. The firm has a market cap of $337.77 million, a price-to-earnings ratio of -9.26 and a beta of 3.34. Calyxt has a 52-week low of $10.21 and a 52-week high of $27.23.

Calyxt Company Profile

Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for plants in the United States. It engages in the development of high oleic soybeans, high fiber wheat, herbicide tolerant wheat, powdery mildew resistant wheat, improved oil composition canola, herbicide tolerant canola, improved quality alfalfa and herbicide tolerant alfalfa, late blight resistant potatoes, cold storable/reduced browning potatoes, improved protein composition soybeans, drought tolerant soybeans, herbicide tolerant soybeans, and improved yield soybeans.

Read More: Earnings Per Share (EPS)

Get a free copy of the Zacks research report on Calyxt (CLXT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Calyxt (NASDAQ:CLXT)

Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.